|
|
 |
|
Viewing report
|
|
|
|
Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in Singapore
Frost & Sullivan, Dec 2009, Pages: 57
This research service aims to provide an update on the epidemiology of Hepatitis C, including the prevalence and incidence, Market Engineering measurements, and government initiatives. It also covers patient source, load, and forecasts, while also outlining the key treaters involved. Current diagnostic methods are presented, followed by treatment regimens, their cost, and upcoming product launches. Clinical trials highlighting research into new treatments are also provided, along with an analysis of the pipeline. Additionally, there is a competitive analysis which includes the market structure, major participants, and future trends. This service covers the Hepatitis C therapeutics market in Singapore
This Frost & Sullivan research service titled Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in Singapore provides an overview of the Hepatitis C market, government initiatives, patient load and classification, patient forecasts, treatment regimens, product launches, and challenges faced by physicians. In this research, Frost & Sullivan's expert analyst provides a list of current and pipeline products for Hepatitis C therapeutics.
This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Service program. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services program ensures that you and your Growth Team™ are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth.
Market Overview
Rising Incidence of Hepatitis C Opens up the Market for Novel and Effective Treatments with Increased Compliance
The Singapore Government’s thrust on education and encouragement for health check-ups have increased the number of Hepatitis C Virus (HCV) diagnosed cases in the country, expanding the patient pool. Therapeutics companies have their task cut out in this market because the high dosage frequency, debilitating side effects, and lackluster efficacy often result in non-compliance of extended treatment, which is often needed for 50 percent of patients with HCV genotype 1 - the most prevalent genotype in Singapore. “According to physicians, those afflicted with Hepatitis C genotype 1 have a sustained viral response of 50 percent to current therapies, resulting in prolonged treatment and noncompliance,” says the analyst of this research. “With 75 percent of those diagnosed with Hepatitis C in Singapore having genotype 1 strain, the current drug offerings are unable to capture a sizeable portion of the market.” The current treatment regimen of Pegylated Interferon and Ribavirin for Hepatitis C have strong side effects such as autoimmune syndromes and neuropsychiatric disorders, and much lower efficacy for the genotype 1 strain, engendering noncompliance. These issues translate to missed treatment opportunities.
Companies that explore new treatments, which improve efficacy, decrease side effects, and increase compliance, are expected to succeed in the market. Refined versions of current HCV drugs, oral formulations of small molecule inhibitors, and a new drug class known as protease inhibitors are in the pipeline and represent the future of HCV treatment. Creating incentives for patients to continue the course of the current HCV treatment will increase the rate of patient compliance with new and improved treatments. “To increase their HCV market share with newer drugs, companies must make sure that patients are aware of their disease status and are willing to try new treatments,” notes the analyst. “Creating marketing campaigns that highlight better efficacy as well as partnerships with governments to lower costs and increase distribution will enhance their market presence.”
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in Hong Kong
Hepatitis C Therapeutics Market—Thailand
Multi-client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in South Korea
Multi-client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in Malaysia
Hepatitis C Therapeutics Market – Taiwan
Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in India
Multi Client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in China
Multi-Client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in the Philippines
Hepatitis C Virus and Therapeutics - Global Strategic Business Report
R&D Trends: Hepatitis C
|
|
|
|
